These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 32053033)

  • 1. Emerging therapeutic targets for NASH: key innovations at the preclinical level.
    Horn P; Newsome PN
    Expert Opin Ther Targets; 2020 Mar; 24(3):175-186. PubMed ID: 32053033
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis.
    Gaul S; Leszczynska A; Alegre F; Kaufmann B; Johnson CD; Adams LA; Wree A; Damm G; Seehofer D; Calvente CJ; Povero D; Kisseleva T; Eguchi A; McGeough MD; Hoffman HM; Pelegrin P; Laufs U; Feldstein AE
    J Hepatol; 2021 Jan; 74(1):156-167. PubMed ID: 32763266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of Nucleotide-Binding Oligomerization Domain-Like Receptor Family Pyrin Domain Containing 3 Inflammasome in the Pathogenesis of Liver Diseases.
    Shi C; Yang H; Zhang Z
    Front Cell Dev Biol; 2020; 8():139. PubMed ID: 32211410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis.
    Koh EH; Yoon JE; Ko MS; Leem J; Yun JY; Hong CH; Cho YK; Lee SE; Jang JE; Baek JY; Yoo HJ; Kim SJ; Sung CO; Lim JS; Jeong WI; Back SH; Baek IJ; Torres S; Solsona-Vilarrasa E; Conde de la Rosa L; Garcia-Ruiz C; Feldstein AE; Fernandez-Checa JC; Lee KU
    Gut; 2021 Oct; 70(10):1954-1964. PubMed ID: 33208407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of pyroptosis in liver diseases.
    Al Mamun A; Wu Y; Jia C; Munir F; Sathy KJ; Sarker T; Monalisa I; Zhou K; Xiao J
    Int Immunopharmacol; 2020 Jul; 84():106489. PubMed ID: 32304992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Emerging Relevance of AIM2 in Liver Disease.
    Lozano-Ruiz B; González-Navajas JM
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32906750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lytic cell death in metabolic liver disease.
    Gautheron J; Gores GJ; Rodrigues CMP
    J Hepatol; 2020 Aug; 73(2):394-408. PubMed ID: 32298766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Candidacy for Pharmacologic Therapies for NASH.
    Rowe IA; Wong VW; Loomba R
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1209-1217. PubMed ID: 33711479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP-Activated Protein Kinase Signaling Pathway.
    Lan T; Yu Y; Zhang J; Li H; Weng Q; Jiang S; Tian S; Xu T; Hu S; Yang G; Zhang Y; Wang W; Wang L; Zhu Q; Rong X; Guo J
    Hepatology; 2021 Aug; 74(2):686-703. PubMed ID: 33576035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell Death in Liver Diseases: A Review.
    Shojaie L; Iorga A; Dara L
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33353156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation.
    Park HS; Song JW; Park JH; Lim BK; Moon OS; Son HY; Lee JH; Gao B; Won YS; Kwon HJ
    Autophagy; 2021 Sep; 17(9):2549-2564. PubMed ID: 33190588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis.
    Knorr J; Wree A; Tacke F; Feldstein AE
    Semin Liver Dis; 2020 Aug; 40(3):298-306. PubMed ID: 32526788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B virus X protein promotes liver cell pyroptosis under oxidative stress through NLRP3 inflammasome activation.
    Xie WH; Ding J; Xie XX; Yang XH; Wu XF; Chen ZX; Guo QL; Gao WY; Wang XZ; Li D
    Inflamm Res; 2020 Jul; 69(7):683-696. PubMed ID: 32347316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNFAIP3 Interacting Protein 3 Overexpression Suppresses Nonalcoholic Steatohepatitis by Blocking TAK1 Activation.
    Liu D; Zhang P; Zhou J; Liao R; Che Y; Gao MM; Sun J; Cai J; Cheng X; Huang Y; Chen G; Nie H; Ji YX; Zhang XJ; Huang Z; Xu H; She ZG; Li H
    Cell Metab; 2020 Apr; 31(4):726-740.e8. PubMed ID: 32268115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Berberine Inhibits Nod-Like Receptor Family Pyrin Domain Containing 3 Inflammasome Activation and Pyroptosis in Nonalcoholic Steatohepatitis
    Mai W; Xu Y; Xu J; Zhao D; Ye L; Yu G; Wang Z; Lu Q; Lin J; Yang T; Gu C; Liu S; Zhong Y; Yang H
    Front Pharmacol; 2020; 11():185. PubMed ID: 32194416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic Steatohepatitis: A Review.
    Sheka AC; Adeyi O; Thompson J; Hameed B; Crawford PA; Ikramuddin S
    JAMA; 2020 Mar; 323(12):1175-1183. PubMed ID: 32207804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major roles of kupffer cells and macrophages in NAFLD development.
    Park SJ; Garcia Diaz J; Um E; Hahn YS
    Front Endocrinol (Lausanne); 2023; 14():1150118. PubMed ID: 37274349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity.
    Tilg H; Adolph TE; Dudek M; Knolle P
    Nat Metab; 2021 Dec; 3(12):1596-1607. PubMed ID: 34931080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies.
    Gutiérrez-Cuevas J; Lucano-Landeros S; López-Cifuentes D; Santos A; Armendariz-Borunda J
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy.
    Pinter M; Pinato DJ; Ramadori P; Heikenwalder M
    Clin Cancer Res; 2023 Feb; 29(3):513-520. PubMed ID: 36166660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.